Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?

Table 2 Efficacy of other, new mesalazine formulations for induction and maintenance of remission in mild-to-moderate UC

Study	Phase	Patient number (n)	Dosing regimen (g/d)	Duration	Remission rates (%)
Induction
Kruis[27]	III	388	Granules 3 od	8 wk	79.1
			Granules 3 tid Salofalk®		75.7
Maintenance					Patients still in remission
Dignass[30]	III	388	Granules 2 od	12 mo	73.8a
			Granules 2 bid		63.6
			Pentasa®
Kruis[29]	III	647	Granules 3.0 od	12 mo	74.7
			Granules 1.5 od		60.8
			Granules 1.5 tid		68.8
			Salofalk®

^aP < 0.05, od vs bid.